Table 1 Patient characteristics

miR-19a

0.620 ± 0.07

4.537 ± 0.98

< 0.0001

miR-126

2.386 ± 0.31

13.26 ± 2.80

< 0.0001

Sex (m/f)

15/7

18/4

n.s.

Age (years)

67 ± 1.7

62 ± 1.9

< 0.05

History of stroke (%)

13.6

9.0

n.s.

History of MI (%)

18.1

4.5

n.s.

CAD (%)

50.0

31.8

n.s.

Hypertension (%)

100

100

n.s.

PAD (%)

27.2

22.7

n.s.

Diabetic neuropathy (%)

81.8

77.2

n.s.

Diabetes years

15 ± 2.3

11 ± 2.1

n.s.

BMI (kg/m²)

30.2 ± 1.3

34.2 ± 1.7

n.s.

CRP (mg/dL)

0.83 ± 0.2

1.0 ± 0.5

n.s.

HbA1c (%)

7.7 ± 0.2

8.7 ± 0.3

n.s.

HbA1c (mmol/mol)

61.1 ± 3.1

72.3 ± 3.9

n.s.

Fasting blood glucose (mg/dL)

144 ± 12

146 ± 6

n.s.

ACE-inhibitor (%)

40.9

50.0

n.s.

AT II antagonist (%)

31.8

31.8

n.s.

Diuretics (%)

54.5

72.7

n.s.

Statins (%)

54.5

50.0

n.s.

Anti-diabetic drugs: insulin (%)

72.7

68.1

n.s.

Metformin (%)

36.3

68.1

< 0.05

Sulfonylureas (%)

27.2

4.5

< 0.05

Acarbose (%)

13.0

9.0

n.s.

Glinides (%)

4.5

13.6

n.s.